Sector
PharmaceuticalsOpen
₹155Prev. Close
₹157Turnover(Lac.)
₹7.91Day's High
₹165.35Day's Low
₹15552 Week's High
₹18452 Week's Low
₹106.2Book Value
₹57.3Face Value
₹10Mkt Cap (₹ Cr.)
125.64P/E
0EPS
0.17Divi. Yield
017 Aug 2023
12:00 AM
AGM
Announcement Date: 17 Aug, 2023
2 Sep 2023
12:00 AM
BookCloser
20 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 38.21 | 38.8 | 38.58 | 26.2 |
Net Worth | 46.21 | 46.8 | 46.58 | 34.2 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 181.56 | 167.21 | 112.17 | 106.89 |
yoy growth (%) | 8.58 | 49.06 | 4.93 | 7.45 |
Raw materials | -107.76 | -96.48 | -69.68 | -67.53 |
As % of sales | 59.35 | 57.7 | 62.12 | 63.18 |
Employee costs | -15.26 | -13.3 | -9.34 | -8.73 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 17.27 | 14.09 | 2.36 | 1.78 |
Depreciation | -3.37 | -3.2 | -2.67 | -2.44 |
Tax paid | -3.55 | -3.19 | -0.65 | -0.43 |
Working capital | 10.52 | 12.18 | 7.8 | -5.96 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 8.58 | 49.06 | 4.93 | 7.45 |
Op profit growth | 19.19 | 170.64 | 17.86 | 0.43 |
EBIT growth | 17.93 | 240.9 | 12.5 | 25.41 |
Net profit growth | 25.86 | 535.77 | 26.77 | 649.08 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
S K Hari Krishna
Director (Technical)
A Parvatisem
Chairman & Independent Directo
K. Ramakrishnam Raju
Non Executive Director
Raju S Kakarlapudi
Managing Director & CEO
Srikakarlapudi Sirisha
Independent Director
Venkatasatyanarayana Murthy Chayaly
Company Sec. & Compli. Officer
Abdur Rahman
Independent Director
SUNDARA PRASAD VENKATA SATYA SRIKAKOLAPU
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Everest Organics Ltd
Summary
Everest Organics Ltd was incorporated at Hyderabad in Feb.93. It was promoted by S K Srihari Raju and S K Chittiramabhadra Raju. The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediaries. The Company commenced its commercial operations in the year 1993. It set up a plant at Aroor, Andhra Pradesh to manufacture bulk drugs and formulations. It came out with a public issue in Jan.95 to part-finance the project.Commercial production of ciprofloxacin and omerprazole commenced in Feb.96. The company preferred to manufacture para hydroxy phynyl glycin (PHPG), but due to market conditions, it decided to drop manufacturing of PHPG and has decided to enhance the capacity of ciprofloxacin from 30 tpa to 120 tpa and also to manufacture enrofloxacin/naproxen.The company increased its installed capacity of Benzimidazole by 60 tpa there by taking its capacity to 120 tpa. The installed capacity of Omeprazole Op Sulphide was increased from 15 TPA to 30 TPA. It introduced one more new product by name Esomeprazole Magnesium by creating additional facility by making investment in plant & machinery in 2007-08.
Read More
What is the Everest Organics Ltd share price today?
The Everest Organics Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹157.05 today.
What is the Market Cap of Everest Organics Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Everest Organics Ltd is ₹125.64 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Everest Organics Ltd?
The PE and PB ratios of Everest Organics Ltd is 0 and 2.74 as of 22 Jul ‘24
What is the 52 Week High and Low of Everest Organics Ltd?
The 52-week high/low is the highest and lowest price at which a Everest Organics Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Everest Organics Ltd is ₹106.2 and ₹184 as of 22 Jul ‘24
What is the CAGR of Everest Organics Ltd?
Everest Organics Ltd's CAGR for 5 Years at 0.92%, 3 Years at -23.34%, 1 Year at 24.95%, 6 Month at 6.26%, 3 Month at 24.60% and 1 Month at 12.10%.
What is the shareholding pattern of Everest Organics Ltd?
The shareholding pattern of Everest Organics Ltd is as follows:
Promoters - 74.15 %
Institutions - 0.06 %
Public - 25.79 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
